- Home
- KRYS vs WD Comparison
KRYS vs WD Comparison
Compare KRYS & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- WD
- Stock Information
- Founded
- KRYS 2015
- WD 1937
- Country
- KRYS United States
- WD United States
- Employees
- KRYS N/A
- WD N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- WD Finance: Consumer Services
- Sector
- KRYS Health Care
- WD Finance
- Exchange
- KRYS Nasdaq
- WD Nasdaq
- Market Cap
- KRYS 4.5B
- WD 3.6B
- IPO Year
- KRYS 2017
- WD 2010
- Fundamental
- Price
- KRYS $148.39
- WD $95.39
- Analyst Decision
- KRYS Strong Buy
- WD Hold
- Analyst Count
- KRYS 7
- WD 3
- Target Price
- KRYS $206.67
- WD $109.00
- AVG Volume (30 Days)
- KRYS 292.3K
- WD 182.4K
- Earning Date
- KRYS 02-24-2025
- WD 02-13-2025
- Dividend Yield
- KRYS N/A
- WD 2.73%
- EPS Growth
- KRYS N/A
- WD N/A
- EPS
- KRYS 1.77
- WD 2.80
- Revenue
- KRYS $241,519,000.00
- WD $986,066,000.00
- Revenue This Year
- KRYS $485.65
- WD N/A
- Revenue Next Year
- KRYS $58.64
- WD $11.61
- P/E Ratio
- KRYS $83.69
- WD $34.03
- Revenue Growth
- KRYS 2722.80
- WD N/A
- 52 Week Low
- KRYS $107.50
- WD $85.63
- 52 Week High
- KRYS $219.34
- WD $118.19
- Technical
- Relative Strength Index (RSI)
- KRYS 37.81
- WD 45.93
- Support Level
- KRYS $141.72
- WD $85.63
- Resistance Level
- KRYS $152.94
- WD $96.30
- Average True Range (ATR)
- KRYS 5.22
- WD 2.52
- MACD
- KRYS -0.42
- WD 0.51
- Stochastic Oscillator
- KRYS 33.00
- WD 73.56
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company's products consist of first mortgage loans, second trust loans, supplemental financings, construction loans, mezzanine loans, and bridge/interim loans. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.